In planning ovarian cancer treatment, it is important to select an appropriate method that can present an accurate HRD phenotype of cancers to predict sensitivity to PARP inhibitors so that patients who are most likely to benefit from treatment could be selected. This evidence concerns the gene PARP1 and ovarian carcinoma.